Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/10499091211035309 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alzheimer's disease drug development in an evolving therapeutic landscape.
Alzheimers Dement (N Y)
November 2024
Alzheimer's Association Chicago Illinois USA.
Unlabelled: The Alzheimer's disease (AD) research field has entered a new era, where our fundamental understanding of the pathophysiology of AD and advances in biomarkers have not only allowed for earlier, timely, and accurate detection and diagnosis of the disease, but that amyloid removal has been shown to be associated with signals of slowing cognitive and functional decline. Although recent FDA-approved amyloid plaque-lowering monoclonal antibody therapies have shifted the trajectory of AD, additional treatment options will be key to further slowing clinical decline or stopping disease progression. Thus, new and emerging therapies for AD have created an evolving therapeutic landscape.
View Article and Find Full Text PDFBuilding a community of practice to address alcohol harms in Canada: Experience from the Canadian Alcohol Policy Evaluation project.
Can J Public Health
December 2024
Government of British Columbia, Ministry of Health, Victoria, BC, Canada.
Setting: Alcohol is a major cause of health and social costs and harms in Canada. While research and awareness of harms caused by alcohol are on the rise, few transdisciplinary platforms exist that are committed to facilitating bold alcohol policy change to reduce health inequities and improve lives.
Intervention: In response to feedback heard during engagement for the Canadian Alcohol Policy Evaluation project, an alcohol policy-focused community of practice (CoP) was launched in January 2022.
Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review.
Pharmaceut Med
November 2024
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Background: In the context of biosimilar use and switching, a patient's negative perception of a biosimilar might trigger a nocebo effect, where negative expectations unrelated to its pharmacologic action may lead to worsened symptoms, resulting in less perceived therapeutic benefit or worsened adverse events. Considering the crucial role biosimilars have in reducing health care costs and expanding access to safe biologics globally, it is essential to develop and implement effective strategies to mitigate the possible occurrence of such nocebo effects.
Objective: The aim of this systematic literature review was two-fold: (i) to review strategies that have been applied and/or tested for minimising the nocebo effect in clinical practice, within and outside the context of biosimilar switching, and (ii) to propose recommendations on useful mitigation strategies to minimise the occurrence of the nocebo effect in the context of biosimilar switching.
Outputs from a model of co-research with older care-experienced people in Sweden to advance eldercare services.
Res Involv Engagem
November 2024
Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
Background: Within the contemporary policy turn towards co-production and co-research in Sweden, older people, practitioners and researchers alike have expressed uncertainty about how to undertake co-research. Moreover, scepticism persists about the merits and contributions of co-research and co-production to research and service development. In this paper, we aim to describe a co-research model developed with older care-experienced lay co-researchers and explore the utility of our model's outcomes to social care research and practice.
View Article and Find Full Text PDFEthics Roundtable State-Erected Barriers to End-of-Life Care.
Am J Hosp Palliat Care
October 2024
Palliative Medicine, Ballad Health System, Johnson City, TN, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!